Number of VDC-ICE cycles completed/patient |
Number of VDC-ICE cycles
completed/patient |
|
|
<8 cycles |
<8 cycles |
5 (36) |
5
(36) |
8 cycles
|
8 cycles
|
9 (64)
|
9 (64)
|
Additional concurrent regimen administered |
Additional concurrent
regimen administered |
|
|
Yes
|
Yes
|
3 (21)
|
3 (21)
|
No
|
No
|
11 (79)
|
11 (79)
|
Planned chemotherapy dose per cycle, median (range) |
Planned
chemotherapy dose per cycle, median (range) |
|
|
cyclophosphamide (mg/m2)
|
cyclophosphamide (mg/m2)
|
1500 (1200-2100)
|
1500 (1200-2100)
|
doxorubicin (mg/m2)
|
doxorubicin (mg/m2)
|
45 (45-75)
|
45 (45-75)
|
ifosfamide (gm/m2)
|
ifosfamide (gm/m2)
|
6 (6-6)
|
6 (6-6)
|
vincristine (mg/m2)
|
vincristine (mg/m2)
|
4.5 (2-4.5)
|
4.5 (2-4.5)
|
carboplatin (AUC target, mg/ml-min)
|
carboplatin (AUC target, mg/ml-min)
|
6 (6-6)
|
6 (6-6)
|
etoposide (mg/m2)
|
etoposide (mg/m2)
|
300 (300-300)
|
300 (300-300)
|
Received dexrazoxane |
Received dexrazoxane |
14 (100) |
14
(100) |
Received growth factor after every cycle |
Received growth factor after
every cycle |
14 (100) |
14 (100) |
Cumulative chemotherapy dose (for patients who completed treatment),
median (range) |
Cumulative chemotherapy dose (for patients who
completed treatment), median (range) |
|
|
cyclophosphamide (mg/m2)
|
cyclophosphamide (mg/m2)
|
6000 (4800-8400)
|
6000 (4800-8400)
|
ifosfamide (g/m2)
|
ifosfamide (g/m2)
|
24 (21-24)
|
24 (21-24)
|
doxorubicin dose (mg/m2)
|
doxorubicin dose (mg/m2)
|
270 (135-450)
|
270 (135-450)
|
Received radiation |
Received radiation |
9 (64) |
9 (64) |
Primary site, n (%) |
Primary site, n (%) |
9 (64) |
9
(64) |
Flank |
Flank |
2 (22) |
2 (22) |
Other |
Other |
7 (78) |
7 (78) |
Metastatic site, n (%) |
Metastatic site, n (%) |
3 (21) |
3 (21) |
Lung |
Lung |
2 (67) |
2 (67) |
Bone |
Bone |
1 (33) |
1 (33) |
Timing of radiation, n (%) |
Timing of radiation, n (%) |
|
|
Pre-chemotherapy
|
Pre-chemotherapy
|
1 (11)
|
1 (11)
|
During chemotherapy
|
During chemotherapy
|
7 (78)
|
7 (78)
|
Post-chemotherapy
|
Post-chemotherapy
|
1 (11)
|
1 (11)
|
Age at radiation (years), median (range) |
Age at radiation (years),
median (range) |
3.4 (1.6-11.2) |
3.4 (1.6-11.2) |
Underwent surgical resection, n (%) |
Underwent surgical
resection, n (%) |
10 (71) |
10 (71) |
Complete resection
|
Complete resection
|
7 (54)
|
7 (54)
|
Gross resection
|
Gross resection
|
2 (15)
|
2 (15)
|
Unknown
|
Unknown
|
1 (8)
|
1 (8)
|
Timing of surgical resection, n (%) |
Timing of surgical
resection, n (%) |
|
|
Upfront
|
Upfront
|
6 (60)
|
6 (60)
|
After neoadjuvant chemotherapy
|
After neoadjuvant chemotherapy
|
4 (40)
|
4 (40)
|
Age at surgery (years), median (range) |
Age at surgery (years), median
(range) |
1.7 (0.3-9.3) |
1.7 (0.3-9.3) |
Biopsy only, n (%) |
Biopsy only, n (%) |
4 (31) |
4
(31) |